Online ISSN 2313-1519
Print    ISSN 1812-2892
Abstract - Prognostic Factors and Survival of Women with Breast Cancer Under 40 Years Old: A Single-Centre Experience
Berrin Inanc, Ozlem Mermut



Objective: This retrospective research aimed to evaluate the results of treatment outcome and clinicopathological features of breast cancer patients under 40 years old.

Material and methods: A total of 80 patients who were receiving radiotherapy and/or chemotherapy treatment for breast cancer (<40 years old) were included in the study. 

Results: First-degree relatives with breast cancer history (p=0.028), oestrogen receptor positivity (p=0.012) and progesterone receptor positivity (p=0.017) were associated with overall survival. No prognostic factors were found in the multivariate Cox regression analysis for overall survival. In multivariate Cox regression analysis, we found breast-conserving surgery type (hazard ratio = 6.104. 95% confidence interval = 1.037–53.928, p=0.045), lymphovascular invasion presence (hazard ratio = 0.127, 95% confidence interval = 0.016–1.025, p=0.005) and curative radiotherapy doses (hazard ratio = 185.976, 95% confidence interval = 5.342–6474.1, p=0.004) as independent prognostic factors for disease-free survival. Overall, survival of 1, 3 and 5 years was 88%, 74% and 65%, respectively. Median was 48±2.6 (42.8–53.19) months. Also, 1-, 3- and 5-year disease-free survival was 85%, 67% and 27%, respectively. Median was 30±1.8 (27.4–32.5) months.

Conclusion: Breast cancer patients under the age of 40 years are highly heterogeneous and are a complex patient group. The prognosis is worse in these patients, and prognostic factors and pathological subtypes should be taken into consideration when making treatment decisions.

Key words: breast cancer, prognostic factors, younger patients


Corresponding author: Berrin Inanc, MD, Department of Radiation Oncology, S.B.U. Istanbul Education Research Hospital, Istanbul, TR–34098, Turkey. Tel.: 902124596692. E-mail:




1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020; 70:7-30.

2. Leong SP, Shen ZZ, Liu TJ, Agarwal G, Tajima T, Paik NS, et al. Is Breast Cancer the Same Disease in Asian and Western Countries? World J Surg. 2010; 34:2308–2324.

3. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009; 27:1160–1167.

4. Gnerlich J, Deshpande A, Jeffe D, Sweet A, White N, Margenthaler J. Elevated breast cancer mortality in young women (<40 yrs) compared with older women is attributed to poorer survival in early stage disease. J Am Coll Surg. 2009; 208(3):341-7.

5. Rodrэґguez-Cuevas S, Macэґas CG, Franceschi D, Labastida S. Breast Carcinoma Presents a Decade Earlier in Mexican Women than in Women in the United States or European Countries. Cancer. 2001; 91:863–868.<863::AID-CNCR1074>3.0.CO;2-Y

6. Chia KS, Du WB, Sankaranarayanan R, Sankila R, Wang H, Lee J, et al. Do younger female breast cancer patients have a poorer prognosis? Results from a population-based survival analysis. Int J Cancer. 2004; 108:761–765. 

7. Chung M, Chang HR, Bland KI, Wanebo HJ. Younger women with breast carcinoma have a poorer prognosis than older women. Cancer. 1996; 77:97–103.<97::AID-CNCR16>3.0.CO;2-3

8. Brewer HR, Jones ME, Schoemaker MJ, Ashworth A, Swerdlow AJ. Family history and risk of breast cancer: an analysis accounting for family structure. Breast Cancer Res Treat. 2017; 165(1):193–200.

9. Vila J, Gandini S, Gentilini O. Overall survival according to type of surgery in young (≤ 40 years) early breast cancer patients: a systematic metaanalysis comparing breastconserving surgery versus mastectomy. Breast. 2015; 24:175–181.

10. Laurberg T, Lyngholm CD, Christiansen P, Alsner J, Overgaard J. Longterm agedependent failure pattern after breastconserving therapy or mastectomy among Danish lymphnodenegative breast cancer patients. Radiother Oncol. 2016; 120:98–106.

11. Schoppmann SF, Bayer G, Aumayr K, et al. Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg. 2004; 240(2):306–312.

12. Fein DA, Fowble BL, Hanlon AL, et al. Identification of women with T1-T2 breast cancer at low risk of positive axillary nodes. J Surg Oncol. 1997; 65:34–39.;2-p

13. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011; 378(9804):1707–16.

14. Bartelink H, Horiot JC, Poortmans PM, Struikmans H, Van den Bogaert W, Fourquet A, et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol. 2007; 25(22):3259–65.

15. Davidson NE, O’Neill AM, Vukov AM, Osborne CK, Martino S, White DR, et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol. 2005; 23:5973–5982.

16. Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011; 378:771–784.

17. Hernandez-Aya LF, Chavez-MacGregor M, Lei X, Meric-Bernstam F, Buchholz T, Hsu L, et al. Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol. 2011; 29:2628–2634.

18. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010; 363:1938–1948.

19. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer. 2007; 109:1721–1728.

Volume 3, Number 57 (2020)